Top 2 Health Care Stocks That May Crash In Q1

As of Jan. 2, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga • Jan 2, 2026

Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott's proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ: EXAS). Julie & Holleman has already identified conflicts and believes the $105 per share deal price may be too low.

GlobeNewsWire • Dec 30, 2025

Should You Continue to Hold EXAS Stock in Your Portfolio Now?

Exact Sciences is investing heavily in R&D and commercial capabilities to boost Cologuard adoption, but competition and macro pressures cloud the outlook.

Zacks Investment Research • Dec 30, 2025

Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) test in breast cancer. Findings from the NSABP B-59 substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group (GBG), demonstrated that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early.

Business Wire • Dec 11, 2025

Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 3, 2025

Top 2 Health Care Stocks You May Want To Dump This Month

As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga • Dec 2, 2025

EXAS Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Exact Sciences to Abbott Laboratories

MONSEY, N.Y., Nov. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Exact Sciences Corporation (Nasdaq: EXAS) (“Exact Sciences”) to Abbott Laboratories for $105.00 per share in cash.

GlobeNewsWire • Nov 24, 2025

Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts across its Precision Oncology portfolio at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place from December 9-12 in San Antonio, Texas. The data to be presented builds upon Exact Sciences' long-standing commitment to backing innovation with strong clinical evidence and commitment to equitable breast cancer care. This commitme.

Business Wire • Nov 24, 2025

Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Exact Sciences Corporation (NasdaqCM: EXAS) to Abbott Laboratories (NYSE: ABT). Under the terms of the proposed transaction, shareholders of Exact Sciences will receive $105.00 in cash for each share of Exact Sciences that they own. KSF is seeking to determine whether this consideration and the proc.

Business Wire • Nov 22, 2025

Why the Stock Price of This Cancer Screening Company Soared 17% Thursday

Shares of cancer screening test maker Exact Sciences Corp. (EXAS) surged Thursday after Abbott Laboratories (ABT) announced a deal to acquire the company for about $21 billion.

Investopedia • Nov 20, 2025